---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-24-000005"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:09:04.974842+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M

## Summary
- Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).
- 2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.
- LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.
- Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.
- Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001759425-24-000005
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/mirm-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-24-000005
- JSON: https://secwatch.observer/filing/0001759425-24-000005.json
- Plain text: https://secwatch.observer/filing/0001759425-24-000005.txt

## Key facts
- Earnings Releases
  Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).
  - Period: the quarter and year ended December 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.